PE20240223A1 - Composiciones farmaceuticas de un inhibidor de cinasa - Google Patents

Composiciones farmaceuticas de un inhibidor de cinasa

Info

Publication number
PE20240223A1
PE20240223A1 PE2023001561A PE2023001561A PE20240223A1 PE 20240223 A1 PE20240223 A1 PE 20240223A1 PE 2023001561 A PE2023001561 A PE 2023001561A PE 2023001561 A PE2023001561 A PE 2023001561A PE 20240223 A1 PE20240223 A1 PE 20240223A1
Authority
PE
Peru
Prior art keywords
compound
composition
pharmaceutical compositions
kinase inhibitor
present
Prior art date
Application number
PE2023001561A
Other languages
English (en)
Spanish (es)
Inventor
Iswadi Liejanto
Tzu-Yuan Chen
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of PE20240223A1 publication Critical patent/PE20240223A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2023001561A 2020-11-05 2021-11-04 Composiciones farmaceuticas de un inhibidor de cinasa PE20240223A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063110124P 2020-11-05 2020-11-05
PCT/US2021/057996 WO2022098828A1 (en) 2020-11-05 2021-11-04 Pharmaceutical compositions of a kinase inhibitor

Publications (1)

Publication Number Publication Date
PE20240223A1 true PE20240223A1 (es) 2024-02-16

Family

ID=78820880

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001561A PE20240223A1 (es) 2020-11-05 2021-11-04 Composiciones farmaceuticas de un inhibidor de cinasa

Country Status (16)

Country Link
US (1) US20230398108A1 (enExample)
EP (1) EP4240333A1 (enExample)
JP (1) JP2023548855A (enExample)
KR (1) KR20230104186A (enExample)
CN (1) CN116406261A (enExample)
AU (1) AU2021374669A1 (enExample)
CA (1) CA3196001A1 (enExample)
CL (1) CL2023001268A1 (enExample)
CO (1) CO2023005942A2 (enExample)
CR (1) CR20230223A (enExample)
GE (1) GEAP202316262A (enExample)
IL (1) IL302485A (enExample)
MX (1) MX2023005273A (enExample)
PE (1) PE20240223A1 (enExample)
TW (1) TW202227061A (enExample)
WO (1) WO2022098828A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEAP202415420A (en) * 2018-01-26 2024-12-25 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009722A1 (en) * 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
US11564915B2 (en) * 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
WO2016079687A1 (en) * 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
GEAP202415420A (en) 2018-01-26 2024-12-25 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
EP4631505A3 (en) 2018-12-13 2025-12-10 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
US20220072002A1 (en) * 2018-12-24 2022-03-10 Chia Tai Tianqing Pharmaceuticalgroup Co., Ltd. Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound

Also Published As

Publication number Publication date
JP2023548855A (ja) 2023-11-21
WO2022098828A1 (en) 2022-05-12
CL2023001268A1 (es) 2023-12-11
CA3196001A1 (en) 2022-05-12
CR20230223A (es) 2023-07-07
CO2023005942A2 (es) 2023-05-19
EP4240333A1 (en) 2023-09-13
TW202227061A (zh) 2022-07-16
KR20230104186A (ko) 2023-07-07
AU2021374669A9 (en) 2024-04-18
CN116406261A (zh) 2023-07-07
MX2023005273A (es) 2023-05-23
IL302485A (en) 2023-06-01
GEAP202316262A (en) 2023-08-10
US20230398108A1 (en) 2023-12-14
AU2021374669A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
PE20211757A1 (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
ECSP20001149A (es) Compuestos antiproliferativos y métodos para utilizarlos
MX2024010045A (es) Compuestos de quinazolina y uso de los mismos como inhibidores de proteinas mutantes kras.
MX2022014444A (es) Sal de malato de n-(4-{[6,7-bis(metiloxi) quinolin-4-il] oxi}fenil)-n'-(4-fluorofenil) ciclopropano-1,1-dicarboxamida, y sus formas cristalinas para el tratamiento de cancer.
CO2021010415A2 (es) Inhibidor jak y método de preparación del mismo
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
JOP20220282A1 (ar) مركبات مفيدة لتثبيط كيناز ret
MX2020007947A (es) Inhibidores de erbb/btk.
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
AR126251A1 (es) Inhibidores de cdk2
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
PE20220962A1 (es) Formas de sales cristalinas de un inhibidor de cinasas
PE20161170A1 (es) Composiciones farmaceuticas que comprenden azd9291
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
NZ607794A (en) N-acylsulfonamide apoptosis promoters
BR112022008786A2 (pt) Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose
CU20170026A7 (es) Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
AR058338A1 (es) Derivados de pirrol fusionado, composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la quinasa.
BR112018010650A8 (pt) pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
CL2024001481A1 (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
MX2024011179A (es) Compuestos multiciclicos
AR126849A1 (es) Compuestos de quinazolina para tratamiento de enfermedad